Shares of Genocea Biosciences Inc (NASDAQ:GNCA) have earned a consensus rating of “Buy” from the seven brokerages that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $4.20.
A number of research firms have recently weighed in on GNCA. Zacks Investment Research downgraded Genocea Biosciences from a “hold” rating to a “sell” rating in a research note on Wednesday, July 11th. HC Wainwright set a $5.00 price target on Genocea Biosciences and gave the company a “buy” rating in a research note on Thursday, August 2nd.
NASDAQ:GNCA opened at $0.65 on Monday. Genocea Biosciences has a 52-week low of $0.49 and a 52-week high of $1.39. The company has a debt-to-equity ratio of 0.95, a quick ratio of 6.84 and a current ratio of 6.84. The firm has a market cap of $54.57 million, a price-to-earnings ratio of -0.33 and a beta of 1.00.
Genocea Biosciences (NASDAQ:GNCA) last posted its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.02. On average, analysts expect that Genocea Biosciences will post -0.47 earnings per share for the current year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in GNCA. California State Teachers Retirement System increased its position in shares of Genocea Biosciences by 166.6% in the 1st quarter. California State Teachers Retirement System now owns 125,569 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 78,469 shares in the last quarter. LMR Partners LLP bought a new position in Genocea Biosciences during the 2nd quarter worth about $175,000. Schwab Charles Investment Management Inc. bought a new position in Genocea Biosciences during the 1st quarter worth about $177,000. DRW Securities LLC bought a new position in Genocea Biosciences during the 2nd quarter worth about $205,000. Finally, Paloma Partners Management Co bought a new position in Genocea Biosciences during the 2nd quarter worth about $343,000. Institutional investors and hedge funds own 60.23% of the company’s stock.
About Genocea Biosciences
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.
Read More: Fundamental Analysis – How It Helps Investors
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.